ResearcherTUM KlinikumActive in the last 2 years
Derya Kabacaoğlu
Matched on ORCID iD 0000-0002-3601-0265; OpenAlex author ID A5089552574. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 35
2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 6
- The role of inflammatory factors in the tumor microenvironment of pancreatic cancer. Co-author DOI 10.3389/fimmu.2025.1625114↗
- Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325564↗
- Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2022.100815↗
- Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. Co-author DOI 10.1053/j.gastro.2021.03.051↗
- NF-κB/Rel Transcription Factors in Pancreatic Cancer: Focusing on RelA, c-Rel, and RelB. Co-author DOI 10.3390/cancers11070937↗
- Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Co-author DOI 10.3389/fimmu.2018.01878↗
Closest collaborators
The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hana Algül · 5 shared papers, 2018–2023 · strength 0.58
- Paper NF-κB/Rel Transcription Factors in Pancreatic Cancer: Focusing on RelA, c-Rel, and RelB. DOI 10.3390/cancers11070937↗
- Paper Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. DOI 10.1136/gutjnl-2021-325564↗
- Paper Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. DOI 10.3389/fimmu.2018.01878↗
- Jiaoyu Ai · 3 shared papers, 2019–2025 · strength 0.49
- Paper The role of inflammatory factors in the tumor microenvironment of pancreatic cancer. DOI 10.3389/fimmu.2025.1625114↗
- Paper NF-κB/Rel Transcription Factors in Pancreatic Cancer: Focusing on RelA, c-Rel, and RelB. DOI 10.3390/cancers11070937↗
- Paper Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. DOI 10.1053/j.gastro.2021.03.051↗
- Dietrich Alexander Ruess · 4 shared papers, 2018–2022 · strength 0.46
- Paper NF-κB/Rel Transcription Factors in Pancreatic Cancer: Focusing on RelA, c-Rel, and RelB. DOI 10.3390/cancers11070937↗
- Paper Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. DOI 10.3389/fimmu.2018.01878↗
- Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
- Kıvanç Görgülü · 3 shared papers, 2021–2023 · strength 0.32
- Paper Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. DOI 10.1136/gutjnl-2021-325564↗
- Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
- Paper Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. DOI 10.1053/j.gastro.2021.03.051↗
- Bruno Sáinz · 3 shared papers, 2021–2023 · strength 0.32
- Paper Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. DOI 10.1136/gutjnl-2021-325564↗
- Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
- Paper Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. DOI 10.1053/j.gastro.2021.03.051↗
- Boxing Zhang · 1 shared paper, 2025 · strength 0.27
- Yuzhang Yuan · 1 shared paper, 2025 · strength 0.27
- Sonja M. Wörmann · 2 shared papers, 2021–2023 · strength 0.21
- Sonia Alcalá · 2 shared papers, 2021–2023 · strength 0.21
- Katrin J. Ciecielski · 2 shared papers, 2018–2021 · strength 0.21
- Marina Lesina · 2 shared papers, 2021–2022 · strength 0.20
- Marta Alonso‐Nocelo · 1 shared paper, 2023 · strength 0.12
- Patricia Sancho · 1 shared paper, 2023 · strength 0.12
- Mert Erkan · 1 shared paper, 2023 · strength 0.12
- Sara Maria David Trabulo · 1 shared paper, 2023 · strength 0.12
- Sandra Valle · 1 shared paper, 2023 · strength 0.12
- Patrick Christian Hermann · 1 shared paper, 2023 · strength 0.12
- Juan Carlos López-Gil · 1 shared paper, 2023 · strength 0.12
- Alfredo Carrato · 1 shared paper, 2023 · strength 0.12
- Christopher Heeschen · 1 shared paper, 2023 · strength 0.12
- Paola Martinelli · 1 shared paper, 2023 · strength 0.12
- Julie Earl · 1 shared paper, 2023 · strength 0.12
- Wolfgang Weber · 1 shared paper, 2022 · strength 0.11
- Katrin J. Frank · 1 shared paper, 2022 · strength 0.11
- Antonio Mulero‐Sánchez · 1 shared paper, 2022 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.